Nexplanon 68 MG implants
Ended Awarded
- Contract number
- SPE2DR26FBPNF
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $14,172
Award facts
- Contract value 100% obligated
- $14,171.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $14,171.60 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Nexplanon 68 mg implants. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of December 8, 2025, and was awarded on November 14, 2025. No set-aside designation was used for this procurement, indicating the award was made through full and open competition. This delivery order was issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which carries a ceiling value of $499,999,999 and extends through December 31, 2036.
DMS Pharmaceutical Group serves as a critical pharmaceutical supplier within the federal military medical supply chain, leveraging its small business status to compete effectively across the Defense Logistics Agency's extensive procurement activities. The company maintains a comprehensive product portfolio encompassing branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables distributed to Department of Defense healthcare facilities worldwide. Under the PPV-G GEN V program—a $30.3 billion acquisition strategy—DMS Pharmaceutical Group functions as a regional prime vendor contractor positioned to fulfill the diverse and specialized pharmaceutical requirements of military healthcare operations. The vendor has demonstrated substantial federal contracting capability through numerous delivery orders issued by the Defense Logistics Agency's Medical Supply Chain division, ranging from purchases under $100 to awards exceeding $115,000.
Quick answers
Who was awarded contract SPE2DR26FBPNF?
SPE2DR26FBPNF was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 14, 2025.
How much is contract SPE2DR26FBPNF worth?
The government has obligated $14,172 on SPE2DR26FBPNF.
Is contract SPE2DR26FBPNF an order under another contract?
Yes. SPE2DR26FBPNF is a delivery order under SPE2DR25D9309, an indefinite delivery contract.
Was contract SPE2DR26FBPNF competed?
The extent of competition for SPE2DR26FBPNF was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award